Approval · Notice of Compliance 18106 · 2016
PMS-MEMANTINE: Notice of Compliance 18106
Issued May 17, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18106
- Date
- May 17, 2016
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Revisions to the product monograph and labels
- Canadian reference product
- EBIXA (Lundbeck Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PMS-MEMANTINE | Not yet assigned | — |
Medicinal ingredients
- MEMANTINE HYDROCHLORIDE 5 MG per TAB
- MEMANTINE HYDROCHLORIDE 10 MG per TAB